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ABSTRACT
Seventy-two chronic myeloid leukemia patients were enrolled as part of a larger randomized trial at 3 centers
between March 1996 and July 2001 to undergo either HLA-matched related allogeneic bone marrow (BM) or
filgrastim (granulocyte colony-stimulating factor)–mobilized peripheral blood stem cell (PBSC) transplanta-
tion. Forty patients received BM, and 32 patients received PBSCs. There was no statistically significant
difference in the incidence of acute or chronic graft-versus-host disease (GVHD), overall survival, disease-free
survival, or non–relapse-related mortality between patients receiving BM or PBSC transplants. The cumulative
incidence of grade II to IV acute GVHDwas 49% in BM and 55% in PBSC recipients (P .48). The cumulative
incidence of clinical extensive chronic GVHD was 50% in BM and 59% in PBSC recipients (P  .46). Among
62 chronic phase chronic myeloid leukemia patients, there was no significant difference in overall survival (87%
versus 81%; P  .59), disease-free survival (80% versus 81%; P  .61), or non–relapse-related mortality (13%
versus 19%; P  .60) by cell source (BM versus PBSCs). Among chronic phase patients, however, there was a
trend toward a higher cumulative incidence of relapse at 3 years in BM recipients (7% versus 0%; P  .10) and
a higher cumulative incidence of chronic GVHD in PBSC recipients (59% versus 40%; P  .11). The trend
toward a higher relapse incidence in BM recipients persisted with a longer follow-up.
© 2005 American Society for Blood and Marrow Transplantation
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PNTRODUCTION
Peripheral blood stem cells (PBSCs) are increas-
ngly selected as a source of hematopoietic stem
ells for transplantation. The potential beneﬁts of
BSCs include ease of collection, fewer adverse
vents reported in donors receiving granulocyte
olony-stimulating factor [1], and more rapid he-
atologic and immune reconstitution [2,3]. A major
oncern has been whether the absolute increase in
-cell dose in PBSC products results in increased
cute or chronic graft-versus-host disease (GVHD).
owever, an increased T-cell dose may translate l
B&MTnto fewer relapses via enhanced graft-versus-leuke-
ia (GVL) effects. Most retrospective and subse-
uent randomized studies have reported no increase
n the incidence of acute GVHD among patients
eceiving PBSC and have reported equivocal results
ith regard to the incidence of chronic GVHD
3-8]. Only 1 study has found improved overall
urvival (OS) in PBSC recipients, as a consequence
f lower non–relapse-associated mortality (NRM)
5]. Two studies have suggested that disease-free
urvival (DFS) was improved in patients receiving
BSCs for the treatment of advanced myeloid ma-
ignancies [4,5]. We report an update of results
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8rom a prospectively deﬁned cohort of chronic
hase (CP) and accelerated phase (AP) chronic my-
loid leukemia (CML) patients enrolled in a ran-
omized trial at the Fred Hutchinson Cancer Re-
earch Center (FHCRC), City of Hope National
edical Center (COHNMC), and Stanford Uni-
ersity Medical Center (SUMC) [4].
ATIENTS AND METHODS
tudy Design
Seventy-two CML-CP and -AP patients were en-
olled in an extended randomized trial at the FHCRC,
he COHNMC, and SUMC. Accrual began in March
996. The initial randomized trial compared bone
arrow (BM) and PBSCs for several hematologic ma-
ignancies, including CML [4]. These CML patients
nd subsequent CML CP or AP patients were en-
olled onto an extended randomized study comparing
he 2 sources of stem cells to address engraftment,
VHD, and GVL effects speciﬁcally in patients with
ML. Fifty-seven of the 72 patients were previously
eported as part of the initial randomized trial [4]. The
xtended study was closed early in July 2001 because
f slow accrual, which was due in part to publication of
he initial randomized study that suggested the beneﬁt
f PBSC and in part to the increased use of imatinib
esylate. The study protocol was reviewed and ap-
roved by the institutional review boards of all partic-
pating centers. Fifty-four patients were treated at the
HCRC, 11 at the COHNMC, and 7 at SUMC.
nrollment criteria for patients and donors were as
reviously described [4].
reatment and Supportive Care
Sixty-eight patients received busulfan 4 mg/kg
y mouth in divided doses daily for 4 days (total
ose, 16 mg/kg) and cyclophosphamide 60 mg/kg
nce daily intravenously days 1 and 2 (total dose,
20 mg/kg). Busulfan was targeted at 900 ng/mL as
reviously described [9]. Four patients received to-
al body irradiation (total dose, 1320 cGy) and eto-
oside (total dose, 60 mg/kg).
Standard techniques for marrow and PBSC col-
ection [4] and GVHD prophylaxis with cyclosporin
nd methotrexate were as previously described
10,11]. For GVHD analysis, the number and du-
ation of GVHD therapies were calculated. For this
nalysis, the number of therapies reﬂected any
hange in treatment, such as reinstitution of immu-
osuppressive therapy, an increase in steroid dose,
r initiation of a new therapy [12]. Antibiotics and
nfection prophylaxis were administered according
o each center’s policies for prevention of bacterial,
ungal, and viral infections. p
6onitoring for Persistent or Recurrent CML
Disease relapse was monitored by pathology, cy-
ogenetics, and qualitative reverse transcriptase-poly-
erase chain reaction (RT-PCR) on days 28 and 80,
t 6-month intervals up to 2 years, and then yearly
fter 2 years. FHCRC patients were also monitored by
uantitative PCR. The techniques of qualitative and
uantitative RT-PCR for bcr-abl have been previously
ublished [13,14]. For analysis, relapse was deﬁned as
ematologic relapse, as cytogenetic relapse character-
zed by the presence of 5 or more Philadelphia chro-
osomes on a single cytogenetic analysis, or as the
resence of any Philadelphia chromosome on at least
consecutive cytogenetic evaluations [4,14].
anagement of Chronic GVHD
Patients with chronic GVHD received treatment for
t least 9 months unless a change in therapy was indi-
ated. As previously documented [12], secondary chronic
VHD therapy was initiated for the progression of
ymptoms after at least 2 weeks of therapy, an absence of
mprovement after 1 month of therapy, persistent symp-
oms after 9 to 12 months of therapy after an initial
mprovement, or the recurrence of symptoms after ces-
ation of immunosuppressive therapy.
uality of Life
Karnofsky performance status (KPS) was mea-
ured at each institution for almost all patient visits.
or patients who underwent transplantation at the
HCRC, an annual patient health questionnaire that
ddresses quality-of-life issues was instituted in 2000.
he questionnaire addresses several areas: activity as
elated to overall health, current symptoms, medical
omplications, and other aspects of life as they relate
o overall health. Speciﬁc questions address health
ehavior and general quality of life, including suicidal
houghts, memory difﬁculties, concerns about sexual
unction, worries about health status and insurance
overage, other medical problems, and ability to func-
ion at work, home, or school. Whenever possible, the
ourth-year questionnaire was selected to compare
utcomes between PBSC and BM recipients. If this
uestionnaire was not available, then the third- or
fth-year questionnaire was used.
tatistical Analysis
Estimates of OS and DFS were calculated by the
aplan-Meier method [15]. The cumulative incidences
f acute and chronic GVHD, relapse, and NRM were
stimated by the methods described in Prentice and
albﬂeisch [16]. The statistical signiﬁcance of differ-
nces in event rates was evaluated with the proportional
azards regression model. Death was treated as a com-
eting risk in the analysis of acute and chronic GVHD
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Allogeneic Related BM/PBSC Transplantation for CML
Bnd relapse. Relapse was treated as a competing risk in
he analysis of chronic GVHD and NRM. All P values
re based on likelihood ratio statistics and are 2 sided.
ntention-to-treat analysis was used for all comparisons.
he trial was designed to enroll 50 patients per study
rm to have 80% power to detect a deleterious difference
ith respect to the rate of relapse, ie, a rate of 25%
based on a binomial difference) in PBSC recipients
ompared with an expected rate of 5% in BM recipients.
owever, because of a longer-than-anticipated accrual
ime, accrual was limited to 72 patients (40 BM and 32
BSC recipients). The power to detect a deleterious
ifference with respect to relapse was 67%. For the
ubanalysis of CP patients only (30 BM and 32 PBSC
ecipients), the power was 59%.
ESULTS
atient Outcomes
The median patient age was 43 years (range, 18-61
ears) and was not signiﬁcantly different between the
BSC and BM recipients. The median time from
iagnosis to transplantation was 6 months (range, 2-92
onths). For CP patients, the time from diagnosis to
ransplantation was not signiﬁcantly different between
he BM and PBSC groups. The median time to trans-
lantation was 6.0 months (range, 2.5-28.4 months)
or BM recipients and 8.2 months (range, 3.0-51.9
onths) for PBSC recipients. Sixty-two patients were
n CP, and 10 patients were in AP. In the CP group,
0 patients received BM and 32 patients received
BSC transplants. All 10 AP patients were random-
zed to BM (P  .001).
Outcomes by cell source are reported in Table 1.
ll patients engrafted. The time intervals from trans-
lantation to engraftment of both neutrophils and
latelets were shorter in the PBSC group. The median
ime to neutrophil engraftment was 21.5 days in the
M group, compared with 16.5 days in the PBSC
roup (P  .03). The median time to platelet engraft-
ent was 21.0 days in the BM group, compared with
4.0 days in the PBSC group (P .26). Because of the
nexpected randomization of all 10 AP patients to the
M arm, a subanalysis of CP patients was performed
o assess the effect of cell source on the incidence of
cute and chronic GVHD, NRM, relapse, DFS, and
S in this group.
Among the 30 CML-CP BM recipients, there
ere 4 (13%) nonrelapse deaths, and among the 32
ML-CP PBSC recipients, there were 6 (19%) non-
elapse deaths. The major causes of NRM among all
atients included diffuse alveolar damage/interstitial
neumonitis, infection, and acute GVHD. Four pa-
ients died before day 100: 1 BM recipient on day 37
nd 3 PBSC recipients on days 46, 69, and 94. We
ound no statistically signiﬁcant difference in NRM, d
B&MTFS, OS, or the incidence of acute or chronic GVHD
y cell source among CML patients in CP (Table 1
nd Figure 1). As shown in Figure 2, we found a trend
oward a decrease in relapse in CP PBSC recipients.
s reported in Table 1, the cumulative incidence es-
imate of relapse at 3 years was 7% in CP BM recip-
ents, compared with 0% in PBSC recipients (P 
10). As of last contact, there were 4 (13%) relapses in
P BM recipients, and there was 1 (3%) relapse in CP
BSC recipients. Two relapses occurred in the BM
roup on day 1111 and day 1469. One late relapse
ccurred in the PBSC group on day 1844 (Figure 2).
onitoring and Interventions for Persistent or
ecurrent CML
Four AP and 5 CP patients had recurrent CML.
utcomes and interventions in these 9 patients are
ummarized in Table 2. Three of 4 AP patients died
rom progressive disease. The fourth AP patient was
uccessfully treated for cytogenetic relapse at 12
onths with a rapid taper of immunosuppression,
hich was complicated only by a mild ﬂare of hepatic
VHD. As of last contact 3 years after relapse, this
atient has no molecular evidence of disease detect-
ble by PCR. All 5 CP patients with recurrent CML
ave been successfully treated. Two patients achieved
omplete cytogenetic and molecular remissions, 1
uring treatment with interferon (INF) and the other
uring treatment with imatinib mesylate. The third
atient remains in cytogenetic remission during treat-
ent with INF but has persistent low-level disease
able 1. Outcomes of CML Patients Who Underwent
ransplantation with BM or PBSCs, by Cell Source
Variable BM PBSCs P Value
ngraftment
Neutrophil (d) 21.5 16.5 .03
Platelet (d) 21 14 .26
cute GVHD
Grades >II 49% 55% .48
hronic GVHD
linical extensive
All patients 50% 59% .46
Chronic phase only 40% 59% .11
onrelapse mortality*
All patients 20% 19% .86
Chronic phase only 13% 19% .60
elapse*
All patients 15% 0% .01
Chronic phase only 7% 0% .10
urvival†
All patients 72% 81% .42
Chronic phase only 87% 81% .59
isease-free survival†
All patients 65% 81% .10
Chronic phase only 80% 81% .61
Three-year cumulative incidence estimate.
Three-year Kaplan-Meier estimate.etectable by PCR. The fourth patient had minimal
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8esponse during treatment with INF and cytarabine
ollowed by donor lymphocyte infusion, but subse-
uent treatment with imatinib produced a complete
olecular response. The ﬁfth patient achieved a mo-
ecular remission 4 months after donor lymphocyte
nfusion after unsuccessful treatment with imatinib
nd imatinib and cytarabine during the previous 3
ears. Follow-up for these patients ranges from 3 to 36
onths after initiation of treatment for recurrent
ML.
Posttransplantation qualitative RT-PCR data for
cr-abl were available for analysis for 58 of 62
ML-CP patients enrolled in the randomized trial.
ixteen of 29 BM and 10 of 29 PBSC recipients had at
east 1 positive qualitative PCR test. The probability
f molecular relapse—deﬁned as a single positive
CR test result—was 55% in BM recipients and 35%
n PBSC recipients at 3 years (P  .10; Figure 3).
here was a trend toward a higher probability of
elapse among patients with a single positive qualita-
ive PCR test. However, because of the small number
f relapses, this association did not reach statistical
igniﬁcance. Quantitative RT-PCR data were avail-
ble for analysis in 41 of 44 CML-CP patients who
igure 1. Overall survival and disease-free survival by cell source in
ML-CP patients.nderwent transplantation at the FHCRC. The me-
8ian number of tests performed was 6 (range, 1-17).
here was a trend toward higher bcr-abl transcript
evels in BM recipients compared with PBSC recipi-
nts. The mean of the maximum of all PCR values was
-fold higher in BM recipients than in PBSC recipi-
nts (P  .20).
Twelve (41%) of 29 BM recipients and 9 (31%) of
9 PBSC recipients had 1 positive PCR test on at least
occasion without clinical relapse. All nonrelapsed
atients, except 1 BM recipient, were negative by PCR
esting at last contact at a median of 1307 days (range,
93-2569 days) after transplantation. By quantitative
T-PCR testing, this BM recipient had an undetect-
ble bcr-abl copy number. Only the qualitative PCR
est, which is more sensitive, was positive. In several
tudies, the association between molecular relapse and
linical relapse is not signiﬁcant for patients within 3
onths of transplantation [13]. Nine CP patients (6
M and 3 PBSC recipients) had persistent CML de-
ectable only by PCR more than 100 days after trans-
lantation. All 9 patients achieved a molecular remis-
ion. Four patients were treated with INF for 12
onths, 2 had immunosuppressive medications with-
rawn, and 1 had chronic GVHD during continued
dministration of immunosuppressive medications.
wo patients had a spontaneous molecular remission
ithout intervention or evidence of GVHD. These 2
atients had only intermittently positive PCR tests.
raft-versus-Host Disease
Thirty-nine patients had evidence of clinical ex-
ensive chronic GVHD. Four patients were ex-
luded from this analysis because of death before
ay 100 (1 BM recipient and 3 PBSC recipients).
he cumulative incidence of chronic GVHD at 3
ears was 50% in BM recipients and 59% among
BSC recipients (P  .46). Among CP patients, the
ncidence of chronic GVHD at 3 years was 40% in
M recipients and 59% among PBSC patients (P Figure 2. Relapse by cell source in CML-CP patients.
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Allogeneic Related BM/PBSC Transplantation for CML
B11). Information regarding the number and timing
f chronic GVHD therapies was available for 29 of
9 patients (15 BM and 14 PBSC recipients).
mong the 29 patients, the median number of
VHD therapies administered (n  2; range, 1-6)
able 2. Outcomes and Interventions in 9 Relapsed Patients
Patient
No.
Disease
Phase at
Transplantation
Cell
Source Relapse
1 AP BM H on day 75 Chem
2 AP BM Day 317 INF
te
3 AP BM H on day 257
4 AP BM C on day 370 Imm
ta
5 CP BM H on day 432 INF
fol
ult
im
6 CP BM C on day 1469 INF
7 CP BM C on day 379 Imm
ta
im
im
ult
8 CP BM C on day 1111 INF
9 CP PBSCs C on day 1844 Imm
ta
br
an
im
indicates hematologic relapse; C, cytogenetic relapse; CCyR, co
no evident disease; Ara-C, cytarabine; DLI, donor lymphocyte
igure 3. The probability of molecular relapse, deﬁned as a single
ualitative PCR test, in CML-CP BM and PBSC recipients (P f10).
B&MTas the same for BM and PBSC recipients, but
here was a trend toward more GVHD therapy in
he PBSC group (P  .13). Data with regard to
mmunosuppression duration and cessation were
vailable for 38 of 39 GVHD patients (20 BM and
8 PBSC recipients). Among surviving patients
ithout evidence of relapse, the percentage of pa-
ients able to discontinue GVHD treatment within
years after transplantation was higher among BM
ecipients (49%) than among PBSC recipients
33%; P  .31); this suggested a trend toward a
onger duration of immunosuppression in PBSC
ecipients.
uality of Life
Karnofsky performance status (KPS) was measured
t each institution for almost all patient visits. Mean
cores are reported at yearly intervals for CP patients by
ell source in Table 3. By year 2, mean KPS was 89%
n both PBSC and BM recipients. We found no statis-
ically signiﬁcant difference in KPS among CP PBSC
ecipients as compared with BM recipients, except in the
ement Response Outcome
apy Death—lymphoid blast
crisis; 9 mo
iation of
chloroma
Death—extramedullary
relapse; 18 mo
Death—myeloid blast
crisis; 10 mo
pression CCyR and CMR NED at last contact 3 y
after relapse
a-C
by DLI, and
y by
Minimal response to
INF/Ara-C and
DLI; CMR to
imatinib
NED at last contact
after imatinib
initiated; significant
marrow cytopenias
and fibrosis
CCyR; low-level
molecular disease
by quantitative
PCR
Molecular disease only
at last contact 28 mo
after relapse;
continues on INF
pression
owed by
and Ara-C,
alone, and
y DLI
CCyR and CMR NED at last contact 4
mo after DLI
CCyR and CMR NED at last contact 30
mo after relapse;
INF discontinued
pression
owed by a
rse of INF
ately
CCyR and CMR NED at last contact 3
mo after imatinib
initiated
cytogenetic response; CMR, complete molecular response; NED,
n; INF, interferon.Manag
other
and rad
sticular
unosup
per
and Ar
lowed
imatel
atinib
unosup
per foll
atinib
atinib
imatel
unosup
per foll
ief cou
d ultim
atinib
mpleteourth year.
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9Twenty-ﬁve of 54 patients who underwent trans-
lantation at the FHCRC submitted at least 1 ques-
ionnaire between 3 and 5 years after transplantation
12 BM and 13 PBSC recipients). Of the 44 CP
atients treated at the FHCRC, 23 patients (52%)
ave submitted at least 1 questionnaire (10 BM and 13
BSC recipients). The small number of respondents
imits the statistical power of comparisons between
hese groups. Overall, there were no signiﬁcant dif-
erences in symptom reporting, overall health rating,
bility to work, depression, or emotional well-being
etween the groups stratiﬁed by cell source. Sixty-six
ercent of the respondents rated their health as excel-
ent or very good. Seventy-three percent reported that
heir physical and emotional health only rarely or
ever interfered with their social activities. All re-
orted feeling depressed only some of the time or
ever. Thirty-ﬁve percent reported that they accom-
lished less because of physical health problems, and
7% reported accomplishing less because of emo-
ional health problems. Thirty percent reported some
ifﬁculty with memory. Sixty-two percent were work-
ng full-time and 13% part-time. The remaining re-
pondents were attending school, working part-time,
r working at home. Seventy-four percent of the re-
pondents reported no problems with pain, 30% per-
ent reported worry about health problems, 26% per-
ent reported difﬁculty with sleep, and 39% percent
eported problems with sexual function.
ISCUSSION
Among CP-CML patients, we found no statisti-
ally signiﬁcant difference in the incidence of acute or
hronic GVHD, NRM, or OS between BM and
BSC recipients. However, there was a trend toward
higher cumulative incidence of relapse in BM recip-
ents (7% versus 0%; P .10) and a higher cumulative
ncidence of chronic GVHD in PBSC recipients (59%
ersus 40%; P  .11) at 3 years. The trend toward an
ncreased relapse incidence in BM recipients persists
ith longer follow-up (13% versus 3%; Figure 2).
here have been several multicenter randomized trials
3-6], single-institution randomized trials [7,8], and
able 3. Mean Karnofsky Performance Status for CP Patients by Cell
ource for Years 1 to 5 after Transplantation
Year
BM PBSC
P Valuen Mean KPS n Mean KPS
1 21 78 21 77 .29
2 17 90 18 89 .73
3 9 89 16 95 .14
4 5 100 10 91 .04
5 3 93 4 93 .82etrospective database studies [17,18] comparing out- t
0omes of BM versus PBSC transplants. Most studies
how no difference in acute GVHD. Only 1 random-
zed trial found a statistically signiﬁcant increase in
cute GVHD with the use of PBSCs [6]. With respect
o chronic GVHD, 2 multicenter trials [3,6], the larg-
st retrospective database cohort study [17], and 3
ther retrospective and cohort studies [19-21] have
ound an increased incidence of chronic GVHD with
BSCs. Updates from 2 randomized trials have also
eported that PBSC patients seem to have more pro-
racted or refractory GVHD [12,22]. It remains un-
lear whether the stem cell source affects OS and
FS. One study reported improved OS that was due
o lower NRM in PBSC recipients, and 2 studies have
uggested that with advanced myeloid malignancies,
FS was improved in PBSC recipients [4,5].
Our study focused on a randomized cohort of
ML patients to clarify the risks associated with
BSCs compared with BM as a stem cell source,
articularly in CML-CP patients. Similar to previ-
usly published studies, the data indicate that CML
atients receiving PBSCs, as opposed to BM, en-
raft more quickly and have no clear difference in
he incidence of acute GVHD. In CML-CP pa-
ients, there was no statistically signiﬁcant differ-
nce in the incidence of chronic GVHD or the
umber of chronic GVHD treatments by cell
ource. However, there was a trend toward an in-
reased incidence of chronic GVHD in PBSC re-
ipients (59%) compared with BM recipients (40%;
 .11). There was also a trend in PBSC recipients
oward a longer duration of immunosuppression
ompared with BM recipients. There was no differ-
nce in OS or DFS by cell source. This ﬁnding is
ot surprising given the excellent outcomes for CP
isease, the relatively small number of patients in
his study, and the relatively short follow-up time.
ost notably, however, there was a trend toward
ewer relapses in CP patients receiving PBSCs.
We acknowledge several unanticipated limitations
o this study. The accrual target was not achieved, and
he analysis was performed prematurely with regard to
atient numbers. Thus, differences between the BM
nd PBSC groups may exist that were not identiﬁed in
his analysis. However, CP patients were well matched
y the process of randomization for many assessed
actors. We found no signiﬁcant difference between
M and PBSC recipients for several known factors
hat could alter relapse rates, such as patient age,
iagnosis white blood cell count, or time to transplan-
ation.
Given the impressive progression-free survival of
8% reported for imatinib mesylate at the 30-month
pdate of the IRIS trial [23] and the relatively minimal
ide effects of this drug, quality-of-life issues and out-
omes in patients with recurrent malignancy after
ransplantation have become increasingly important.
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Allogeneic Related BM/PBSC Transplantation for CML
Bhe 5-year OS after transplantation is 75% in both
atched related and unrelated donor recipients, and
elapse after stem cell transplantation occurs in only
0% to 20% of CP-CML patients [24]. All CP pa-
ients and 1 AP patient with recurrent disease were
uccessfully treated. Only 3 AP patients died as a
onsequence of recurrent CML. Our data suggest that
any CML patients participating in this trial have a
ood quality of life, and this ﬁnding does not differ
igniﬁcantly by stem cell source. KPS by year 2 after
ransplantation show that most patients are function-
ng at 90% KPS, irrespective of cell source. KPS,
owever, probably does not adequately address many
f the nonquantiﬁable factors that comprise quality of
ife. Self-report data from the questionnaires, how-
ver, indicated that most respondents rated their
ealth as excellent or good, were working full-time,
nd were not signiﬁcantly limited by health or emo-
ional problems.
The trend toward a higher relapse rate in BM
ecipients may suggest that PBSCs augment the GVL
ffect that is so important in hematopoietic stem cell
ransplantation for the treatment of CML [25,26].
he ﬁndings of a higher probability of molecular
elapse in BM recipients and the trend toward higher
uantitative bcr-abl transcript levels in BM recipients
ay support this possibility.
From these and other data, there does not seem to
e a major disadvantage in using PBSCs rather than
M as a source of stem cells for CML-CP disease. If,
ith longer follow-up and more detailed retrospective
nalysis, the ﬁnding of a lower rate of relapse is sta-
istically signiﬁcant in PBSC recipients, PBSCs may
e the preferred cell source because of a possible
ncreased GVL effect. However, this effect is coun-
erbalanced by an increased incidence of chronic
VHD that has been found to be statistically signif-
cant in other studies.
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